Skip to main content
. 2022 Oct 31;9:1052943. doi: 10.3389/fmed.2022.1052943

Figure 7.

Figure 7

Sensitivity analysis of pooled results for (A) OS, (B) PFS in mCRPC patients and (C) BFS in nmPCa patients. OS, overall survival; PFS, progression-free survival; BFS, biochemical recurrence-free survival; mCRPC, metastatic castration-resistant prostate cancer; nmPCa, non-metastatic prostate cancer.